Bisirna Therapeutics (suzhou) Co., Ltd.
Clinical trials sponsored by Bisirna Therapeutics (suzhou) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection targets hidden heart risk in early trial Results expected Jul 2027 (estimated)
-
New injection targets hidden heart risk in early trial
Disease control OngoingThis early-stage study tests a single dose of BSA204, an experimental injection, in 40 Chinese adults with borderline high lipoprotein(a) – a fatty substance linked to heart disease. The main goal is to check safety and side effects, while also measuring changes in cholesterol le…
Phase 1 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug VSA012 takes first step in human safety trial
Knowledge-focused OngoingThis early-stage study tests VSA012, a drug that targets the complement system (part of the immune system), in 40 healthy volunteers. The main goal is to check safety and how the drug moves through the body after a single dose. It is a first step before testing in patients with c…
Phase 1 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC